Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OmniAb's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OmniAb's regulatory disclosures and financial reporting.
OABI filed a Rule 144 notice to sell 13,542 shares of common stock. The filing lists these as restricted stock issued for compensation with an intended sale date of 04/07/2026. The notice also reports prior sales of 6,990 shares on 02/17/2026 and 9,673 shares on 02/18/2026.
OABI filed a Rule 144 notice to sell 13,542 shares of common stock. The filing lists these as restricted stock issued for compensation with an intended sale date of 04/07/2026. The notice also reports prior sales of 6,990 shares on 02/17/2026 and 9,673 shares on 02/18/2026.
OmniAb, Inc. provides a licensing-based antibody discovery platform used by pharmaceutical, biotech and academic partners to develop next‑generation therapeutics. Its transgenic animal technologies, AI‑driven screening and ion channel expertise are designed to generate fully human, high‑quality antibody candidates across many disease areas.
OmniAb’s business model centers on platform access fees, research services, milestones and downstream royalties on partner products. As of December 31, 2025, the company reported 107 active partners and 407 active programs, including 27 clinical programs, two antibodies under regulatory review and three approved, partner‑commercialized products.
OmniAb, Inc. provides a licensing-based antibody discovery platform used by pharmaceutical, biotech and academic partners to develop next‑generation therapeutics. Its transgenic animal technologies, AI‑driven screening and ion channel expertise are designed to generate fully human, high‑quality antibody candidates across many disease areas.
OmniAb’s business model centers on platform access fees, research services, milestones and downstream royalties on partner products. As of December 31, 2025, the company reported 107 active partners and 407 active programs, including 27 clinical programs, two antibodies under regulatory review and three approved, partner‑commercialized products.
OmniAb, Inc. reported weaker 2025 results but outlined growth plans and tighter cost control. Full-year 2025 revenue was $18.7 million, down from $26.4 million in 2024, mainly due to lower license, milestone and service revenue, partly offset by new xPloration and higher royalty revenue. The company posted a 2025 net loss of $64.8 million, or $0.57 per share, slightly higher than the prior year’s $62.0 million loss.
Research and development expense fell to $47.8 million and general and administrative expense to $29.2 million, helped by lower headcount, share-based compensation and legacy ion channel spending, though results included a $3.9 million impairment. OmniAb ended 2025 with $54.0 million in cash, cash equivalents and short-term investments.
For 2026, OmniAb guides to $25–$30 million in revenue and $80–$85 million in GAAP costs and operating expenses, with non‑GAAP cash costs of $50–$55 million, and expects year-end cash of $30–$35 million and an effective tax rate of approximately 0%. The company highlights 107 active partners, 407 active programs, the launch of its OmniUltra transgenic chicken platform, and multiple partner programs progressing through clinical development.
OmniAb, Inc. reported weaker 2025 results but outlined growth plans and tighter cost control. Full-year 2025 revenue was $18.7 million, down from $26.4 million in 2024, mainly due to lower license, milestone and service revenue, partly offset by new xPloration and higher royalty revenue. The company posted a 2025 net loss of $64.8 million, or $0.57 per share, slightly higher than the prior year’s $62.0 million loss.
Research and development expense fell to $47.8 million and general and administrative expense to $29.2 million, helped by lower headcount, share-based compensation and legacy ion channel spending, though results included a $3.9 million impairment. OmniAb ended 2025 with $54.0 million in cash, cash equivalents and short-term investments.
For 2026, OmniAb guides to $25–$30 million in revenue and $80–$85 million in GAAP costs and operating expenses, with non‑GAAP cash costs of $50–$55 million, and expects year-end cash of $30–$35 million and an effective tax rate of approximately 0%. The company highlights 107 active partners, 407 active programs, the launch of its OmniUltra transgenic chicken platform, and multiple partner programs progressing through clinical development.
OmniAb, Inc. Chief Legal Officer Charles S. Berkman reported multiple equity compensation moves and a small mandated share sale. He acquired 18,750 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs), and was granted 60,000 new RSUs and 600,000 stock options, all held directly.
To cover tax withholding on the RSU vesting, 9,673 common shares were sold in a required "sell-to-cover" transaction at a weighted average price of $1.71, with individual trades between $1.68 and $1.73. After these transactions, he directly owned 392,700 shares of common stock, 124,584 RSUs and 600,000 stock options.
OmniAb, Inc. Chief Legal Officer Charles S. Berkman reported multiple equity compensation moves and a small mandated share sale. He acquired 18,750 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs), and was granted 60,000 new RSUs and 600,000 stock options, all held directly.
To cover tax withholding on the RSU vesting, 9,673 common shares were sold in a required "sell-to-cover" transaction at a weighted average price of $1.71, with individual trades between $1.68 and $1.73. After these transactions, he directly owned 392,700 shares of common stock, 124,584 RSUs and 600,000 stock options.
OmniAb, Inc. Executive VP, Finance and CFO Kurt A. Gustafson reported multiple equity transactions. He acquired 18,750 shares of common stock through the vesting and conversion of restricted stock units and received new awards of 60,000 RSUs and stock options for 600,000 shares.
Following these awards, he sold 9,301 shares of common stock at a weighted average price of $1.71 per share to cover tax withholding obligations under a mandatory sell-to-cover arrangement, which the company’s equity plans require rather than a discretionary trade.
OmniAb, Inc. Executive VP, Finance and CFO Kurt A. Gustafson reported multiple equity transactions. He acquired 18,750 shares of common stock through the vesting and conversion of restricted stock units and received new awards of 60,000 RSUs and stock options for 600,000 shares.
Following these awards, he sold 9,301 shares of common stock at a weighted average price of $1.71 per share to cover tax withholding obligations under a mandatory sell-to-cover arrangement, which the company’s equity plans require rather than a discretionary trade.
OmniAb, Inc. President and CEO Matthew W. Foehr reported multiple equity transactions on February 18, 2026. He acquired 58,333 shares of common stock through the vesting and exercise of restricted stock units (RSUs) and received new awards of 156,250 RSUs and 1,562,500 stock options.
The vested RSUs represent a grant that vests in three substantially equal annual installments beginning on February 18, 2026, while the new RSU grant vests in three substantially equal annual installments beginning on February 18, 2027. The stock option grant becomes exercisable as to 12.5% of the underlying shares six months after the grant date, then in 42 substantially equal monthly installments.
To cover tax withholding obligations from the RSU vesting, 30,843 shares of common stock were sold at a weighted average price of $1.71 per share in transactions priced between $1.68 and $1.73. The filing states these are mandatory sell-to-cover transactions under the company’s equity incentive plans and not discretionary trades.
OmniAb, Inc. President and CEO Matthew W. Foehr reported multiple equity transactions on February 18, 2026. He acquired 58,333 shares of common stock through the vesting and exercise of restricted stock units (RSUs) and received new awards of 156,250 RSUs and 1,562,500 stock options.
The vested RSUs represent a grant that vests in three substantially equal annual installments beginning on February 18, 2026, while the new RSU grant vests in three substantially equal annual installments beginning on February 18, 2027. The stock option grant becomes exercisable as to 12.5% of the underlying shares six months after the grant date, then in 42 substantially equal monthly installments.
To cover tax withholding obligations from the RSU vesting, 30,843 shares of common stock were sold at a weighted average price of $1.71 per share in transactions priced between $1.68 and $1.73. The filing states these are mandatory sell-to-cover transactions under the company’s equity incentive plans and not discretionary trades.
FOEHR MATTHEW W reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 93,670 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 4,375,787 shares.
FOEHR MATTHEW W reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 93,670 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 4,375,787 shares.
GUSTAFSON KURT A reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 33,912 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 259,402 shares.
GUSTAFSON KURT A reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 33,912 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 259,402 shares.
Berkman Charles S reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 34,074 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 383,623 shares.
Berkman Charles S reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 34,074 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 383,623 shares.
OABI filed a notice that an insider plans to sell common shares under Rule 144. The filing lists planned sales of 20,483 and 30,451 common shares through Morgan Stanley Smith Barney, with aggregate market values of 34821.10 and 51766.70, respectively, on the NASDAQ on 02/17/2026 and 02/18/2026.
The shares come from restricted stock granted by the issuer as compensation, including 36,458 securities acquired on 02/16/2026 and 58,333 on 02/18/2026. The filing notes 143,955,400 common shares outstanding. It also discloses a prior sale of 13,666 common shares for gross proceeds of 26798.27 on 12/08/2025.
OABI filed a notice that an insider plans to sell common shares under Rule 144. The filing lists planned sales of 20,483 and 30,451 common shares through Morgan Stanley Smith Barney, with aggregate market values of 34821.10 and 51766.70, respectively, on the NASDAQ on 02/17/2026 and 02/18/2026.
The shares come from restricted stock granted by the issuer as compensation, including 36,458 securities acquired on 02/16/2026 and 58,333 on 02/18/2026. The filing notes 143,955,400 common shares outstanding. It also discloses a prior sale of 13,666 common shares for gross proceeds of 26798.27 on 12/08/2025.